Title
Category
Credits
Event date
Cost
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), and despite a higher HF symptom burden, they are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future.
  • CMHC
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
$0.00
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events. Despite advancements in LDL-C lowering therapies, achieving LDL-C targets remains suboptimal due to clinical inertia and patient non-adherence, contributing to patient's residual ASCVD risk. The landscape of LDL-C lowering therapies is rapidly evolving, with several new and emerging agents that may help bridge these gaps.